Cover Image


Investigation Report on China Sildenafil Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 297277
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
Back to Top
中國的Sildenafil市場分析 Investigation Report on China Sildenafil Market, 2010-2019
出版日期: 2015年05月28日 內容資訊: 英文 20 Pages

在全球各國數億個男性為勃起功能障礙(ED)而感到痛苦,中國也有5000萬人以上的ED患者。以這個巨大的市場為目標,全球各國的企業推進ED治療藥的開發。Pfizer Co., Ltd.所開發的是Sildenafil,當初開發作為PDE5抑制劑,不過,臨床實驗的結果反而是對ED的治療效果受認可,以「Viagra」的商品名在1998年獲得美國FDA(食品藥物管理局)的認證。同年也在中國上市,現在銷售額持續擴大。從2014年學名藥也開始登場,預計今後的價格降低,不過,ED的患者數持續增加,Sildenafil的市場規模今後預期仍持續成長。


第1章 Sildenafil的相關概念

  • 開發過程與症狀
  • 全球市場的銷售情形

第2章 中國的Sildenafil市場概要

  • 專利現況
  • 學名藥的生產情形
  • 主要製造商
  • 市場規模

第3章 Sildenafil的銷售額分析

  • 總銷售額
  • 各地區的銷售額

第4章 主要廠商的市場佔有率分析

第5章 各劑型的市場規模分析

第6章 Sildenafil的醫院用標準價格(各企業)

第7章 中國的Sildenafil市場未來展望

  • 男性勃起功能障礙(ED)的發病率預測
  • 學名藥的製造計劃
  • 市場規模的預測
  • 市場競爭的預測



Product Code: 1505186

Hundreds of millions of adult men suffer from erectile dysfunction (ED) throughout the world and there are also over 50 million ED patients in China. It is shown that among men aged above 35, over 60% suffer from different degrees of ED, among which 50% is due to pure organogenic pathogeny, 30% pure psychogenic factors and 20% both of the former two. Men with ED are prone to sense of inferiority and depression, which influence their emotions and life gravely. Therefore, the sexual dysfunction of adult men can't be ignored. Hence many drug makers' close attention to the drug market of ED.

Sildenafil, developed by Pfizer, has a main indication of ED and other indications like pulmonary hypertension and altitude sickness.

Pfizer sought patent for Viagra from China's State Intellectual Property Office in 1994 and succeed. The Patent Law of China formulates that the valid term for a patent is 20 years, therefore, Viagra's patent shall expire in 2014. During the 20 years, Sildenafil (trade name Viagra) basically monopolized Chinese market. With the expiry of Virgra patent, Sildenafil made by local enterprises is expected to get a slice of Chinese market. According to CRI's survey on sample hospitals, after entering China in 1998, Viagra showed no sudden explosion with a CAGR of about 13.1% during the period of 2006-2014. According to CRI, the main reason lies in this: since Viagra could also be bought without prescription in many pharmacies despite its status as prescription drug as a result of loose control, its sales growth mainly comes from pharmacies instead of hospitals. Viagra has occupied an important position among drugs for sexual dysfunction for a long time in China, therefore many local firms start to make generic drugs in succession. Although Viagra's price will drop as generic drugs start to appear in the Chinese market, Pfizer's market share will still go down for the price of generic drugs made by local firms is lower.

According to CRI's survey, the retail price of Viagra made by Pfizer in China exceeds 100 CNY/pill (100 ml), but that in America is about 8 USD/pill which is equivalent to less than 50 CNY/pill.

In 2004, Pfizer's Viagra was qualified to enter Chinese retail pharmacies. Similar drugs in the market like Bayer's Levitra (Vardenafil) got such qualification in 2006 and Lilly's Cialis (Tadalafil) in 2007.

As the patent protection of Viagra all over the world start to expire, its market share will gradually decrease. A good case in point is the Korean market where up to 28 kinds of generic drugs with different forms and dosages appeared the day after the expiry of Viagra's patent in Korea on May.17, 2012. Since the price of such generic drugs equals only one third of Viagra's price, the sales value of Viagra in that month fell by more than 40% compared with the same period of last year. After Viagra's patent expired, pharmaceutical companies can produce Sildenafil as long as they get complete approval. In Oct. 2014, sildenafil citrate (trade name Jin Ge) made by Guangzhou Bai Yun Shan Pharmaceutical General Factory hit the market. According to the statistics of CRI, by May. 2015, Jiangsu Lianhuan Pharmaceutical Co., Ltd, Sichuan Yuanji Pharmaceutical Pharmaceutical Co., Ltd, the Biochemical Pharmaceutical Factory of Zhuhai SEZ and Beijing Midsky Kangda Medicine Technology Co., Ltd have all applied for the approval of generic drugs of Viagra.

With the economic development, the change of life styles and the increased psychological pressures, the number of ED patients will keep growing in the next few years in China. Besides, as Sildenafil is estimated to add new indications to current ones, its market size will keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • ED incidence in China
  • sales status of Sildenafil in China
  • price of Sildenafil in Chinese hospitals
  • market outlook of Sildenafil in China

The author suggests the following groups of people purchase this report:

  • manufacturers of ED drugs
  • medical institutions
  • investors/ research institutions interested in ED drug market
  • any interest in Chinese medicine market, please contact CRI for customized research service

Table of Contents

1. Related Concepts of Sildenafil

  • 1.1. Development & Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Sildenafil in China

  • 2.1. Patent Status
  • 2.2. Production of Generic Drugs
  • 2.3. Major Manufacturers
  • 2.4. Market Size

3. Survey on Sildenafil's Price in China, 2009-2013

  • 3.1. Sales Value in China
  • 3.2. Sales Value by Regions

4. Major Manufacturers of Sildenafil and Their Market Share in China, 2009-2013

5. Survey on the Market Size of Sildenafil's Dosage Forms in China, 2009-2013

6. Reference Price of Sildenafil in Chinese Hospitals in 2014

7. Market Outlook of Sildenafil in China, 2014-2018

  • 7.1. Forecast of ED Incidence
  • 7.2. Progress of Generic Drugs
  • 7.3. Forecast of Market Size
  • 7.4. Forecast of Market Competition

Selected Charts

  • Chart Price of Sildenafil in Sample Hospitals in China, 2010-2014
  • Chart Sales Volume of Sildenafil in Chinese Market, 2010-2014
  • Chart Price of Viagra in Hospitals in Different Chinese Regions in 2014
  • Chart Forecast of Sildenafil's Market Size in Chinese Hospitals, 2015-2019
Back to Top